Immunomedics (IMMU) Stock Price, News & Analysis

Company Overview

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Key Stats

• Today's Range: $87.86 to $87.86
• 50-Day Range: $85.08 to $87.86
• 52-Week Range: $8.80 to $87.93
• Volume: N/A
• Average Volume: 4.01 million shs
• Market Capitalization: $20.31 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMMU Stock Analysis - Frequently Asked Questions

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) announced its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.39. The biopharmaceutical company had revenue of $20.07 million for the quarter, compared to the consensus estimate of $24.81 million.

What other stocks do shareholders of Immunomedics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunomedics investors own include Bristol Myers Squibb (BMY), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Gilead Sciences (GILD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/05/2020
• Today: 7/08/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic Substances
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMMU
• CIK: 722830
• Web: www.immunomedics.com
• Phone: 973-605-8200
• Fax: N/A
• Employees: 366
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$357.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -132.40%
• Return on Assets: -51.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.84
• Quick Ratio: 12.58

Sales & Book Value

• Annual Sales: $290 thousand
• Price / Sales: 70,028.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.38 per share
• Price / Book: 63.67

Miscellaneous

• Outstanding Shares: 231,144,000
• Free Float: N/A
• Market Cap: $20.31 billion
• Optionable: Optionable
• Beta: 2.90